MARTINSRIED, GERMANY and MUNICH, GERMANY--(Marketwire - September 21, 2012) - Today at 3:00 p.m.
CET (2:00 p.m. BST, 9:00 a.m. EDT), the Management Board of
MorphoSys AG will host a public conference call and webcast to present
information on the results of the clinical phase 1b/2a trial of MorphoSys's
proprietary antibody MOR103 in patients with rheumatoid arthritis, which
was
announced yesterday.
Dial-in numbers for the Conference Call (listen-only):
Germany: +49 (0) 89 2444 32975
For U.K. residents: +44 (0) 20 3003 2666
For U.S. residents: +1 202 204 1514
MorphoSys offers participants the opportunity to follow the presentation
through
a simultaneous slide presentation online at http://www.morphosys.com.
An audio replay and manuscripts of the conference will be
available on
www.morphosys.com/conference-calls in due course.
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology
in
the pharmaceutical industry. By successfully applying this and other
patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
The
Company's AbD Serotec unit uses HuCAL and other technologies to generate
superior monoclonal antibodies for research and diagnostic applications.
Through its own development efforts and successful partnerships in the
pharmaceutical industry, MorphoSys has built a therapeutic pipeline of more
than
70 human antibody drug candidates for the treatment of cancer, rheumatoid
arthritis, and Alzheimer's disease, to name just a few. With its ongoing
commitment to new antibody technology and drug development, MorphoSys is
focused
on engineering the medicines of tomorrow. MorphoSys is listed on the
Frankfurt
Stock Exchange under the symbol MOR. For regular updates about MorphoSys,
visit
http://www.morphosys.com
About MOR103
MOR103 is a fully human antibody against GM-CSF (granulocyte
macrophage-colony
stimulating factor). GM-CSF was originally identified as a growth factor
for
granulocytes and macrophages but has more recently been identified as an
inflammatory mediator in autoimmune disorders such as RA. GM-CSF stimulates
stem
cells to produce granulocytes and other macrophages and subsequently
activates
these differentiated immune cells leading to an increased production of
pro-inflammatory cytokines, chemokines and proteases and thereby ultimately
to
articular destruction. The antibody MOR103 blocks GM-CSF and reduces its
pro-inflammatory activity.
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®,
RapMAT®, arYla®,
Ylanthia® and 100 billion high potentials® are registered
trademarks of
MorphoSys AG.
Slonomics® is a registered trademark of Sloning BioTechnology
GmbH, a
subsidiary of MorphoSys AG.
This communication contains certain forward-looking statements
concerning the
MorphoSys group of companies. The forward-looking statements contained
herein
represent the judgment of MorphoSys as of the date of this release and
involve
risks and uncertainties. Should actual conditions differ from the
Company's
assumptions, actual results and actions may differ from those
anticipated.
MorphoSys does not intend to update any of these forward-looking
statements as
far as the wording of the relevant press release is concerned.
Conference Call Alert:
http://hugin.info/130295/R/1642631/529147.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE
[HUG#1642631]
